{"analyses":[{"ciLowerLimit":"-0.18","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.229","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.104","estimateComment":"The treatment can be considered beneficial if the mean difference (treatment - control) slope is negative.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.82","paramType":"Slope","paramValue":"0.024","statisticalComment":"The treatment effect was determined by testing the significance of the group by time interaction in GEE using a one degree-of-freedom (df) test.","statisticalMethod":"Generalized Estimating Equation (GEE)"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0428","value":"0.5634"},{"groupId":"OG001","spread":"0.0272","value":"0.4989"}]}],"title":"BL"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0453","value":"0.5973"},{"groupId":"OG001","spread":"0.0262","value":"0.4942"}]}],"title":"6m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0487","value":"0.563"},{"groupId":"OG001","spread":"0.0302","value":"0.4969"}]}],"title":"12m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0665","value":"0.593"},{"groupId":"OG001","spread":"0.04","value":"0.507"}]}],"title":"18m"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.0436","value":"0.5561"},{"groupId":"OG001","spread":"0.0354","value":"0.5449"}]}],"title":"24m"}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"A liver function measurement (in mg/dL). The mean is reported by arm at each timepoint with corresponding standard errors.","dispersionType":"Standard Error","groups":[{"description":"Patients received Carvedilol PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG000","title":"Arm I (Carvedilol)"},{"description":"Patients received Placebo PO delivered at 6.25 mg twice daily (for a total dose of 12.5 mg per day) for 24 months.","id":"OG001","title":"Arm II (Placebo)"}],"paramType":"MEAN","populationDescription":"We excluded 31 participants who did not have a second time point assessment of echocardiography, resulting in 151 analyzable participants.","reportingStatus":"POSTED","timeFrame":"Baseline before treatment, 6 months, 12 months, 18 months, 24 months after treatment initiation","title":"Average Bilirubin","type":"SECONDARY","unitOfMeasure":"mg/dL"}